New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
09:06 EDTBMTIBioMimetic Therapeutics initiates enrollment in tendinopathy clinical trial
BioMimetic Therapeutics initiated enrollment in a Phase II clinical trial to assess the safety and efficacy of Augment Chronic Tendinopathy as a treatment for lateral epicondylitis, commonly known as tennis elbow. The randomized, controlled trial is expected to enroll up to 100 patients at seven clinical sites in the U.S. The product candidate is aimed at the large tendinosis market for which there is significant unmet clinical need with limited effective long-term treatments currently available.
News For BMTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for BMTI

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use